Program registry
An open registry of therapeutic viruses and other investigational therapies, licensed under CC BY 4.0. Each program has a stable ID (AXP000001) and lists every name it has gone by, its virus and construct where it is virus-based, its regulatory approvals, the ClinicalTrials.gov trials that name it, and what changed in them week by week.
The curated data and its rules live in the registry folder on GitHub; this week's trial changes are in What changed.
Trials as of the ClinicalTrials.gov snapshot of 2026-11-15. Phase and trial counts use confirmed (automatic) links only.
Explore
Oncolytic virus atlas: every oncolytic virus as a map, joined to its virus family, transgenes, the cancers its trials enrol and more. Phage therapy atlas: the same map for phage therapies, joined to the infections their trials enrol. AAV gene therapy atlas: AAV products by capsid, transgene and disease area.
By disease
Jump to: Adenoviridae · Caudoviricetes · Flaviviridae · Herelleviridae · Herpesviridae · Orthoherpesviridae · Paramyxoviridae · Parvoviridae · Picornaviridae · Poxviridae · Retroviridae · Rhabdoviridae · Spinareoviridae · Straboviridae · Togaviridae · Targeted small molecule
Adenoviridae (84)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| Ad3-hTERT-E1A | AXP000072 | human adenovirus 3 · Ad3 | conditionally replicating | 0 | |||
| Ad5-CD/TKrep | AXP000049 | human adenovirus 5 · Ad5 (CD/TKrep) | replicating | 0 | |||
| Ad5-D24-GMCSF | AXP000066 | human adenovirus 5 · Ad5 | conditionally replicating | 0 | |||
| Ad5-RGD-D24-GMCSF | AXP000068 | human adenovirus 5 · Ad5 (RGD fiber) | conditionally replicating | 0 | |||
| Ad5-yCD/mutTK(SR39)rep-ADP | AXP000047 | human adenovirus 5 · Ad5 (yCD/mutTK(SR39)rep-ADP) | replicating | Phase 1 | 2 | ||
| Ad5-yCD/mutTKSR39rep-hIL12 | AXP000048 | human adenovirus 5 · Ad5 (yCD/mutTKSR39rep-hIL12) | replicating | Phase 1 | 2 | ||
| Ad5/3-Cox2L-D24 | AXP000069 | human adenovirus 5 · Ad5/3 chimera | conditionally replicating | 0 | |||
| Ad5/3-D24-hNIS | AXP000071 | human adenovirus 5 · Ad5/3 chimera | conditionally replicating | 0 | |||
| Ad5/3-E2F-d24-GMCSF | AXP000067 | human adenovirus 5 · Ad5/3 chimera | conditionally replicating | 0 | |||
| Ad5/3-hTERT-E1A-hCD40L | AXP000070 | Ad5/3-hTERT-CD40L | human adenovirus 5 · Ad5/3 chimera | conditionally replicating | 0 | ||
| AdAPT-001 | AXP000040 | human adenovirus 5 · Ad5 (AdAPT-001) | conditionally replicating | Phase 2 | 1 | ||
| Adze1.C | AXP000063 | human adenovirus (serotype not reported) | conditionally replicating | Phase 1 | 1 | ||
| BioTTT001 | AXP000046 | Ad-TD-nsIL12, Ad5-TD-nsIL-12 | human adenovirus 5 · Ad5 (Ad-TD) | conditionally replicating | Phase 2 | 10 | |
| CAdVEC | AXP000042 | human adenovirus 5 · binary oncolytic adenovirus (CAdVEC) | conditionally replicating | Phase 1 | 1 | ||
| CG7060 | AXP000054 | CV706 | human adenovirus 5 · Ad5 (CG7060) | conditionally replicating | 0 | ||
| CG7870 | AXP000053 | CV787 | human adenovirus 5 · Ad5 (CG7870) | conditionally replicating | Phase 1/2 | 2 | |
| CRAd-S-pk7 | AXP000052 | NSC-CRAd-S-pk7, NSC-CRAd-Survivin-pk7 | human adenovirus 5 · Ad5 (CRAd-S-pk7) | conditionally replicating | Phase 1 | 3 | |
| cretostimogene grenadenorepvec | AXP000006 | cretostimogene, CG0070 | human adenovirus 5 · Ad5 (CG0070) | conditionally replicating | Phase 3 | 12 | |
| delolimogene mupadenorepvec | AXP000007 | LOAd703, Oncolytic Adenovirus LOAd703 | human adenovirus 5 · Ad5/35 chimera | conditionally replicating | Phase 1/2 | 4 | |
| enadenotucirev | AXP000012 | EnAd, ColoAd1 | human adenovirus 11 · Ad11p/Ad3 group B chimera (ColoAd1) | conditionally replicating | Phase 1/2 | 5 | |
| GM103 | AXP000043 | human adenovirus 5 | conditionally replicating | Phase 1/2 | 1 | ||
| H101 | AXP000003 | Oncorine, Oncolytic Adenovirus H101, rAd5 H101 | human adenovirus 5 · Ad5 (H101) | conditionally replicating | Phase 4 | yes (NMPA) | 21 |
| H103 | AXP000064 | human adenovirus 2 · Ad2 (H103) | conditionally replicating | 0 | |||
| ICOVIR-5 | AXP000050 | human adenovirus 5 · Ad5 (ICOVIR-5) | conditionally replicating | Phase 1/2 | 2 | ||
| ICOVIR-7 | AXP000051 | human adenovirus 5 · Ad5 (ICOVIR-7) | conditionally replicating | 0 | |||
| ICVB-1042 | AXP000055 | human adenovirus 5 · Ad5 (ICVB-1042) | conditionally replicating | Phase 1 | 1 | ||
| igrelimogene litadenorepvec | AXP000009 | Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT-123 | human adenovirus 5 · Ad5/3 chimera | conditionally replicating | Phase 1/2 | 6 | |
| Ixovex-1 | AXP000057 | human adenovirus 5 · Ad5 (Ixovex-1) | conditionally replicating | Phase 1/2 | 1 | ||
| KD01 | AXP000058 | human adenovirus (serotype not reported) | conditionally replicating | Phase 1 | 2 | ||
| KH901 | AXP000065 | human adenovirus 5 · Ad5 (KH901) | conditionally replicating | 0 | |||
| lontucirev | AXP000033 | CI-1042, ONYX-015, E1B 55kDa mutant adenovirus dl1520 | human adenovirus 5 · Ad2/Ad5 chimera (dl1520) | conditionally replicating | Phase 1 | 1 | |
| MEM-288 | AXP000041 | human adenovirus 5 · Ad5 (MEM-288) | conditionally replicating | Phase 1 | 1 | ||
| NG-350A | AXP000038 | human adenovirus 11 · Ad11p/Ad3 group B chimera (T-SIGn) | conditionally replicating | Phase 1 | 4 | ||
| NG-641 | AXP000039 | human adenovirus 11 · Ad11p/Ad3 group B chimera (T-SIGn) | conditionally replicating | Phase 1 | 3 | ||
| NRG-103 | AXP000060 | human adenovirus (serotype not reported) | conditionally replicating | Phase 1 | 2 | ||
| ONCOS-102 | AXP000035 | Ad5/3-D24-GMCSF, CGTG-102 | human adenovirus 5 · Ad5/3 chimera | conditionally replicating | Phase 2 | 7 | |
| ORCA-010 | AXP000037 | human adenovirus 5 · Ad5 Delta-24-RGD (T1) | conditionally replicating | Phase 1/2 | 1 | ||
| suratadenoturev | AXP000034 | Telomelysin, OBP-301, Telomelycin | human adenovirus 5 · Ad5 (OBP-301) | conditionally replicating | Phase 2 | 8 | |
| SynOV1.1 | AXP000045 | human adenovirus 5 · Ad5 (SynOV1.1) | conditionally replicating | Phase 1 | 1 | ||
| tasadenoturev | AXP000005 | Ad5-Delta24RGD, DNX-2401, Ad5-d24-RGD | human adenovirus 5 · Ad5 Delta-24-RGD | conditionally replicating | Phase 2 | 10 | |
| tezemlimogene daxadenorepvec | AXP000036 | DNX-2440 | human adenovirus 5 · Ad5 Delta-24-RGD | conditionally replicating | Phase 1 | 2 | |
| THEO-260 | AXP000056 | human adenovirus (serotype not reported) | Phase 1/2 | 2 | |||
| TS-2021 | AXP000059 | human adenovirus (serotype not reported) | conditionally replicating | Phase 1 | 1 | ||
| VT-101 | AXP000061 | human adenovirus (serotype not reported) | conditionally replicating | Phase 1 | 2 | ||
| YH-02 | AXP000062 | human adenovirus (serotype not reported) | conditionally replicating | Phase 2 | 1 | ||
| YSCH-01 | AXP000044 | Recombinant L-IFN adenovirus injection | human adenovirus 5 · Ad5 (ZD55/CTGVT) | conditionally replicating | Phase 1/2 | 5 | |
| zabilugene almadenorepvec | AXP000008 | VCN-01 | human adenovirus 5 · Ad5 (VCN-01) | conditionally replicating | Phase 2 | 7 |
In vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| Ad-RTS-hIL-12 | AXP000146 | INXN-2001 | human adenovirus 5 · Ad5 | non replicating | Phase 2 | 8 | |
| aglatimagene besadenovec | AXP000144 | GliAtak, ProstAtak, Virafir | human adenovirus 5 · Ad5 | non replicating | Phase 3 | 13 | |
| alferminogene tadenovec | AXP000151 | Generx, Ad5FGF-4 | human adenovirus 5 · Ad5 | non replicating | Phase 3 | 4 | |
| ASN-002 | AXP000149 | TG1042 | human adenovirus | non replicating | Phase 2 | 10 | |
| contusugene ladenovec | AXP000142 | Advexin, INGN 201, RPR/INGN-201 | human adenovirus 5 · Ad5 | non replicating | Phase 3 | 9 | |
| E10A | AXP000148 | Ad-rhENDO | human adenovirus 5 · Ad5 | non replicating | Phase 3 | 2 | |
| Gendicine | AXP000141 | Genkaxin | human adenovirus 5 · Ad5 | non replicating | Phase 4 | yes (NMPA) | 4 |
| golnerminogene pradenovec | AXP000150 | TNFerade, ADgv EGR.TNF.11D | human adenovirus 5 · Ad5 | non replicating | Phase 3 | 7 | |
| INGN 241 | AXP000153 | human adenovirus 5 · Ad5 | non replicating | Phase 2 | 1 | ||
| nadofaragene firadenovec | AXP000143 | Adstiladrin, nadofaragene firadenovec-vncg, rAd-IFN/Syn3 | human adenovirus 5 · Ad5 | non replicating | Phase 4 | yes (FDA) | 16 |
| ofranergene obadenovec | AXP000145 | Ofra-Vec, VB-111 | human adenovirus 5 · Ad5 | non replicating | Phase 3 | 7 | |
| SCH-58500 | AXP000152 | ACN53 | human adenovirus 5 · Ad5 | non replicating | Phase 2/3 | 3 | |
| sitimagene ceradenovec | AXP000147 | Cerepro | human adenovirus 5 · Ad5 | non replicating | 0 |
Ex vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| AdVTMM2-transduced dendritic cell vaccine | AXP000166 | AdVTMM2 | human adenovirus 5 · Ad5 | non replicating | 0 |
Vaccine vector
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| Ad-MAGEA3 | AXP000165 | AdMA3 | human adenovirus 5 · Ad5 | non replicating | Phase 1/2 | 3 | |
| Ad26.COV2.S | AXP000168 | Jcovden, Ad26COVS1, JNJ-78436735 | human adenovirus 26 · Ad26 | non replicating | Phase 4 | yes (FDA, EMA) | 33 |
| Ad26.Mos4.HIV | AXP000174 | human adenovirus 26 · Ad26 | non replicating | Phase 3 | 8 | ||
| Ad26.RSV.preF | AXP000175 | human adenovirus 26 · Ad26 | non replicating | Phase 3 | 15 | ||
| Ad26.ZEBOV | AXP000172 | Zabdeno, Ad26.ZEBOV-GP | human adenovirus 26 · Ad26 | non replicating | Phase 3 | yes (EMA) | 25 |
| Ad5-EBOV | AXP000173 | human adenovirus 5 · Ad5 | non replicating | Phase 1 | yes (NMPA) | 3 | |
| Ad5-hGCC-PADRE | AXP000164 | human adenovirus 5 · Ad5 | non replicating | Phase 1 | 1 | ||
| Ad5-nCoV | AXP000169 | Convidecia, Convidecia Air | human adenovirus 5 · Ad5 | non replicating | Phase 4 | yes (NMPA, other) | 18 |
| BBV154 | AXP000176 | iNCOVACC | chimpanzee adenovirus | non replicating | Phase 3 | yes (other) | 4 |
| ChAdOx1 nCoV-19 | AXP000167 | Covishield, Vaxzevria, AZD1222 | chimpanzee adenovirus Y25 · ChAdOx1 | non replicating | Phase 4 | yes (MHRA, EMA) | 59 |
| ETBX-011 | AXP000154 | human adenovirus 5 · Ad5 [E1-, E2b-] | non replicating | Phase 2 | 20 | ||
| ETBX-021 | AXP000155 | human adenovirus 5 · Ad5 [E1-, E2b-] | non replicating | Phase 2 | 10 | ||
| ETBX-051 | AXP000156 | human adenovirus 5 · Ad5 [E1-, E2b-] | non replicating | Phase 2 | 20 | ||
| ETBX-061 | AXP000157 | human adenovirus 5 · Ad5 [E1-, E2b-] | non replicating | Phase 2 | 21 | ||
| ETBX-071 | AXP000158 | human adenovirus 5 · Ad5 [E1-, E2b-] | non replicating | Phase 2 | 3 | ||
| Gam-COVID-Vac | AXP000170 | Sputnik V, Gam-COVID-Vac-Lyo, Gam-COVID-Vac-M | human adenovirus 26 · rAd26 (dose 1); rAd5 (dose 2) | non replicating | Phase 3 | yes (other) | 20 |
| GRAd-COV2 | AXP000177 | gorilla adenovirus | non replicating | Phase 2/3 | 2 | ||
| GRT-C903 | AXP000162 | chimpanzee adenovirus C68 · ChAdV68 | non replicating | Phase 1/2 | 2 | ||
| lutadenovec autogene | AXP000161 | GRT-C901 | chimpanzee adenovirus C68 · ChAdV68 | non replicating | Phase 2/3 | 3 | |
| NOUS-209 | AXP000163 | GAd-209-FSP, GAd20-209-FSP, MVA-209-FSP | great ape adenovirus 20 · GAd20 | non replicating | Phase 1/2 | 2 | |
| PRGN-2009 | AXP000160 | gorilla adenovirus | non replicating | Phase 2 | 4 | ||
| Sputnik Light | AXP000171 | human adenovirus 26 · rAd26 | non replicating | Phase 3 | yes (other) | 2 | |
| zopapogene imadenovec | AXP000159 | Papzimeos, zopapogene imadenovec-drba, PRGN-2012 | gorilla adenovirus | non replicating | Phase 4 | yes (FDA) | 4 |
Caudoviricetes (30)
Phage
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| AB-PA01 | AXP000223 | Pseudomonas aeruginosa bacteriophage (cocktail) | replicating | 1 | |||
| AchromoPhage | AXP000240 | Achromobacter bacteriophage (cocktail) | replicating | Phase 1 | 1 | ||
| AP-PA02 | AXP000220 | Pseudomonas aeruginosa bacteriophage (cocktail) | replicating | Phase 2 | 2 | ||
| AP-SA02 | AXP000221 | Staphylococcus aureus bacteriophage (cocktail) | replicating | Phase 1/2 | 1 | ||
| BACTELIDE | AXP000238 | PL-03-BM | bacteriophage cocktail against S. aureus, P. aeruginosa and K. pneumoniae | replicating | Phase 1/2 | 1 | |
| BFC-1 | AXP000247 | cocktail of P. aeruginosa phages 14/1 and PNM and S. aureus phage ISP | replicating | 0 | |||
| BX004 | AXP000217 | BX004-A | Pseudomonas aeruginosa bacteriophage (cocktail) | replicating | Phase 2 | 2 | |
| BX005 | AXP000219 | BX005-A | Staphylococcus aureus bacteriophage (cocktail) | replicating | Phase 1/2 | 1 | |
| BX211 | AXP000218 | Staphylococcus aureus bacteriophage (patient-matched from a phage bank) | replicating | 0 | |||
| DP-QB-MYA-002 | AXP000241 | Mycobacterium abscessus bacteriophage (cocktail) | replicating | Phase 1 | 1 | ||
| DP-QB-PSA-005 | AXP000242 | Pseudomonas aeruginosa bacteriophage (five-phage cocktail) | replicating | Phase 2/3 | 1 | ||
| DP-QB-STA-005 | AXP000243 | Staphylococcus aureus bacteriophage (five-phage cocktail) | replicating | Phase 2/3 | 1 | ||
| DUOFAG | AXP000234 | bacteriophage cocktail against S. aureus and P. aeruginosa | replicating | Phase 1/2 | 1 | ||
| EcoActive | AXP000225 | Escherichia coli bacteriophage (cocktail) | replicating | Phase 1/2 | 1 | ||
| LBP-EC01 | AXP000215 | Escherichia coli bacteriophage (six-phage cocktail) | replicating | Phase 2 | 2 | ||
| MP101 | AXP000236 | Pseudomonas aeruginosa bacteriophage | replicating | Phase 3 | 7 | ||
| Muddy | AXP000246 | Muddy_HRMN0052 | Mycobacterium bacteriophage Muddy | replicating | Phase 1 | 1 | |
| NTR-101 | AXP000237 | bacteriophage preparation against cytolysin-positive Enterococcus faecalis | replicating | Phase 1 | 1 | ||
| PGX-0100 | AXP000239 | phage cocktail-SPK | bacteriophage cocktail of 14 phages against S. aureus, P. aeruginosa and K. pneumoniae | replicating | Phase 1 | 1 | |
| PP1131 | AXP000228 | Pseudomonas aeruginosa bacteriophage (12-phage cocktail) | replicating | 0 | |||
| PP1493 | AXP000229 | Staphylococcus aureus bacteriophage | replicating | Phase 2 | 1 | ||
| PP1815 | AXP000230 | Staphylococcus aureus bacteriophage | replicating | Phase 2 | 1 | ||
| Pyophage | AXP000244 | Pyo bacteriophage | polyvalent bacteriophage cocktail (Pyo) against staphylococci, streptococci and enterococci, E. coli, Proteus mirabilis and P. aeruginosa | replicating | 0 | ||
| ShigActive | AXP000226 | Shigella bacteriophage (cocktail) | replicating | Phase 1/2 | 1 | ||
| SNIPR001 | AXP000216 | Escherichia coli bacteriophage (four-phage cocktail) | replicating | Phase 1/2 | 2 | ||
| TP-102 | AXP000224 | bacteriophage cocktail against P. aeruginosa, S. aureus and A. baumannii | replicating | Phase 2 | 2 | ||
| TP-122A | AXP000232 | TP-122 | Pseudomonas aeruginosa bacteriophage | replicating | Phase 1/2 | 1 | |
| VRELysin | AXP000227 | Enterococcus bacteriophage (cocktail) | replicating | Phase 1/2 | 1 | ||
| WPP-201 | AXP000233 | bacteriophage cocktail of eight phages lytic for P. aeruginosa, S. aureus and E. coli | replicating | Phase 1 | 1 | ||
| WRAIR-PAM-CF1 | AXP000235 | Pseudomonas aeruginosa bacteriophage (cocktail) | replicating | Phase 1/2 | 1 |
Flaviviridae (3)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| West Nile virus Egypt 101 | AXP000131 | West Nile virus · Egypt 101 | replicating | 0 |
Vaccine vector
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| CYD-TDV | AXP000206 | Dengvaxia | yellow fever virus · 17D-204 backbone (CYD-1 to CYD-4 chimeras) | replicating | Phase 3 | yes (EMA, FDA) | 10 |
| Imojev | AXP000207 | Imojev MD, JE-CV, ChimeriVax-JE | yellow fever virus · 17D-204 backbone (JE-CV chimera) | replicating | Phase 4 | yes (other, TGA) | 19 |
Herelleviridae (2)
Herpesviridae (8)
In vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| beremagene geperpavec | AXP000193 | Vyjuvek, B-VEC, KB103 | herpes simplex virus 1 | non replicating | Phase 3 | yes (FDA, EMA, PMDA) | 4 |
| KB105 | AXP000198 | herpes simplex virus 1 | non replicating | Phase 2 | 2 | ||
| KB301 | AXP000199 | herpes simplex virus 1 | non replicating | Phase 1 | 1 | ||
| KB407 | AXP000194 | herpes simplex virus 1 | non replicating | Phase 1 | 2 | ||
| KB408 | AXP000195 | herpes simplex virus 1 | non replicating | Phase 1 | 1 | ||
| KB707 | AXP000196 | herpes simplex virus 1 | non replicating | Phase 1/2 | 2 | ||
| KB801 | AXP000197 | herpes simplex virus 1 | non replicating | Phase 1/2 | 1 | ||
| NP2 | AXP000200 | NP2 enkephalin | herpes simplex virus 1 | non replicating | Phase 2 | 3 |
Orthoherpesviridae (25)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| BS-006 | AXP000090 | herpes simplex virus 2 · HG52 | conditionally replicating | Phase 1/2 | 3 | ||
| C134 | AXP000085 | herpes simplex virus 1 · F | conditionally replicating | Phase 1 | 3 | ||
| CAN-3110 | AXP000087 | rQNestin34.5v.2 | herpes simplex virus 1 · F | conditionally replicating | Phase 1 | 1 | |
| canerpaturev | AXP000076 | HF10, TBI-1401, C-REV | herpes simplex virus 1 · HF10 (derived from HSV-1 strain HF) | replicating | Phase 2 | 9 | |
| G207 | AXP000074 | HSV G207 | herpes simplex virus 1 · F | conditionally replicating | Phase 2 | 6 | |
| HSV1716 | AXP000073 | Seprehvir, RL1 mutant HSV-1 1716 | herpes simplex virus 1 · 17+ | conditionally replicating | Phase 1/2 | 3 | |
| JNJ-87704916 | AXP000092 | herpes simplex virus 1 | conditionally replicating | Phase 1 | 1 | ||
| M032 | AXP000086 | M032-HSV-1 | herpes simplex virus 1 · F | conditionally replicating | Phase 1/2 | 3 | |
| MVR-C5252 | AXP000081 | herpes simplex virus 1 | conditionally replicating | Phase 1 | 2 | ||
| NV1020 | AXP000075 | R7020 | herpes simplex virus 1 · R7020 (HSV-1 F background with HSV-2 sequences) | conditionally replicating | Phase 1/2 | 2 | |
| OH2 | AXP000089 | OH2 injection, oHSV2hGM-CSF | herpes simplex virus 2 · HG52 | conditionally replicating | Phase 4 | 14 | |
| ON-01 | AXP000138 | herpes simplex virus 1 | conditionally replicating | Phase 1/2 | 1 | ||
| ONCR-177 | AXP000084 | herpes simplex virus 1 | conditionally replicating | Phase 1 | 1 | ||
| OrienX010 | AXP000077 | herpes simplex virus 1 · clinical isolate (Chinese Han patient) | conditionally replicating | Phase 2 | 5 | ||
| R130 | AXP000091 | herpes simplex virus 1 | conditionally replicating | Early phase 1 | 8 | ||
| RP3 | AXP000079 | herpes simplex virus 1 · RH018A | conditionally replicating | Phase 2 | 3 | ||
| rRp450 | AXP000088 | herpes simplex virus 1 · KOS | conditionally replicating | Phase 1 | 1 | ||
| STI-1386 | AXP000135 | Seprehvec, Oncolytic HSV-1 STI-1386 | herpes simplex virus 1 | conditionally replicating | Phase 1 | 1 | |
| sturlimogene erparepvec | AXP000078 | herpes simplex virus 1 · RH018A | conditionally replicating | Phase 2/3 | 6 | ||
| T3011 | AXP000080 | MVR-T3011 | herpes simplex virus 1 | conditionally replicating | Phase 2 | 12 | |
| talimogene laherparepvec | AXP000001 | Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC | herpes simplex virus 1 · JS1 | conditionally replicating | Phase 3 | yes (FDA, EMA) | 55 |
| teserpaturev | AXP000002 | Delytact, DS-1647, G47∆ | herpes simplex virus 1 · F | conditionally replicating | yes (PMDA) | 0 | |
| VG161 | AXP000082 | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) | herpes simplex virus 1 | conditionally replicating | Phase 2 | 9 | |
| VG2025 | AXP000083 | herpes simplex virus 1 | conditionally replicating | Phase 2 | 6 | ||
| vusolimogene oderparepvec | AXP000010 | Tudriqev, vusolimogene oderparepvec-wtpg | herpes simplex virus 1 · RH018A | conditionally replicating | Phase 3 | yes (FDA) | 8 |
Paramyxoviridae (11)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| MEDI5395 | AXP000118 | recNDV(GM-CSF) | Newcastle disease virus · LaSota-derived recombinant | replicating | Phase 1 | 1 | |
| MTH-68/H | AXP000116 | Newcastle disease virus · MTH-68/H | replicating | 0 | |||
| mumps virus (Asada series) | AXP000140 | mumps virus | replicating | 0 | |||
| MV-CEA | AXP000112 | Carcinoembryonic Antigen-Expressing Measles Virus | measles morbillivirus · Edmonston-NSe vaccine lineage | replicating | Phase 1 | 2 | |
| MV-NIS | AXP000113 | Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | measles morbillivirus · Edmonston-NSe vaccine lineage | replicating | Phase 2 | 11 | |
| MV-s-NAP | AXP000114 | MV Encoding NAP | measles morbillivirus · Edmonston-NSe vaccine lineage | replicating | Phase 1 | 1 | |
| NDV-HUJ | AXP000117 | Newcastle disease virus · HUJ (lentogenic) | replicating | 0 | |||
| PV701 | AXP000115 | Oncolytic Newcastle Disease Virus Strain PV701 | Newcastle disease virus · PV701 (attenuated MK107 lineage) | replicating | Phase 1 | 2 |
Vaccine vector
Other
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| HVJ-E | AXP000130 | GEN0101 | Sendai virus · HVJ (Z strain lineage), UV-inactivated envelope | non replicating | Phase 2 | 2 |
Parvoviridae (16)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| ParvOryx | AXP000127 | H-1 parvovirus · H-1PV (wild-type) | replicating | Phase 1/2 | 2 |
In vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| 4D-150 | AXP000259 | adeno-associated virus (R100 capsid variant) · R100 | non replicating | Phase 3 | 5 | ||
| alipogene tiparvovec | AXP000248 | Glybera, AMT-011 | adeno-associated virus 1 · AAV1 | non replicating | Phase 2/3 | withdrawn | 5 |
| botaretigene sparoparvovec | AXP000260 | bota-vec, AAV-RPGR, MGT009 | adeno-associated virus 5 · AAV5 | non replicating | Phase 3 | 3 | |
| dalnacogene ponparvovec | AXP000256 | XinJiuning, BBM-H901 | adeno-associated virus | non replicating | Phase 1 | yes (NMPA, other) | 1 |
| delandistrogene moxeparvovec | AXP000254 | Elevidys, SRP-9001 | adeno-associated virus rh74 · AAVrh74 | non replicating | Phase 4 | yes (FDA, PMDA) | 11 |
| eladocagene exuparvovec | AXP000251 | Kebilidi, Upstaza, PTC-AADC | adeno-associated virus 2 · AAV2 | non replicating | Phase 2 | yes (EMA, FDA) | 6 |
| etranacogene dezaparvovec | AXP000253 | Hemgenix, AMT-061 | adeno-associated virus 5 · AAV5 | non replicating | Phase 3 | yes (FDA, EMA) | 6 |
| fidanacogene elaparvovec | AXP000255 | Beqvez, Durveqtix, PF-06838435 | adeno-associated virus rh74 (variant capsid) · AAVRh74var | non replicating | Phase 3 | yes (FDA) | 4 |
| ixoberogene soroparvovec | AXP000258 | ixo-vec, ADVM-022 | adeno-associated virus (7m8 capsid variant) · AAV.7m8 | non replicating | Phase 3 | 8 | |
| laruparetigene zovaparvovec | AXP000261 | AGTC-501, laru-zova | adeno-associated virus | non replicating | Phase 2/3 | 3 | |
| OCU400 | AXP000262 | AAV-hNR2E3 | adeno-associated virus 5 · AAV5 | non replicating | Phase 3 | 3 | |
| onasemnogene abeparvovec | AXP000250 | Itvisma, Zolgensma, OAV-101 | adeno-associated virus 9 · AAV9 | non replicating | Phase 4 | yes (FDA, PMDA, EMA) | 22 |
| surabgene lomparvovec | AXP000257 | ABBV-RGX-314, sura-vec, RGX-314 | adeno-associated virus 8 · AAV8 | non replicating | Phase 3 | 10 | |
| valoctocogene roxaparvovec | AXP000252 | Roctavian, BMN 270 | adeno-associated virus 5 · AAV5 | non replicating | Phase 3 | yes (EMA, FDA) | 7 |
| voretigene neparvovec | AXP000249 | Luxturna, AAV2-hRPE65v2 | adeno-associated virus 2 · AAV2 | non replicating | Phase 3 | yes (FDA, EMA, PMDA) | 6 |
Poxviridae (41)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| ASP9801 | AXP000102 | vaccinia virus | conditionally replicating | Phase 1 | 1 | ||
| BT-001 | AXP000095 | TG6030 | vaccinia virus · Copenhagen | conditionally replicating | Phase 3 | 6 | |
| CF33-CD19 | AXP000101 | onCARlytics, CF33-CD19t | chimeric orthopoxvirus (CF33) · CF33 | conditionally replicating | Phase 1 | 1 | |
| CF33-hNIS | AXP000099 | VAXINIA, HOV2 | chimeric orthopoxvirus (CF33) · CF33 | conditionally replicating | Phase 1 | 2 | |
| CF33-hNIS-antiPDL1 | AXP000100 | CHECKvacc | chimeric orthopoxvirus (CF33) · CF33 | conditionally replicating | Phase 1 | 1 | |
| GC001 | AXP000108 | vaccinia virus | conditionally replicating | Phase 2 | 3 | ||
| GO306 | AXP000109 | vaccinia virus | conditionally replicating | Phase 1 | 1 | ||
| hV01 | AXP000103 | Recombinant human IL-21-expressing oncolytic vaccinia virus injection | vaccinia virus | conditionally replicating | Phase 2 | 3 | |
| IDOV-Immune | AXP000110 | vaccinia virus | conditionally replicating | Phase 1 | 2 | ||
| IDOV-SAFE | AXP000137 | vaccinia virus | conditionally replicating | Phase 1/2 | 3 | ||
| JX-929 | AXP000097 | vvDD-CDSR | vaccinia virus · Western Reserve | conditionally replicating | Phase 1 | 1 | |
| olvimulogene nanivacirepvec | AXP000093 | Olvi-Vec, GLV-1h68, GL-ONC1 | vaccinia virus · Lister (LIVP) | conditionally replicating | Phase 3 | 10 | |
| OTS-412 | AXP000107 | vaccinia virus | conditionally replicating | Phase 1 | 3 | ||
| pexastimogene devacirepvec | AXP000011 | JX-594, TG-6006, Pexa-Vec | vaccinia virus · Wyeth | conditionally replicating | Phase 3 | 20 | |
| PF-07263689 | AXP000105 | vaccinia virus | conditionally replicating | Phase 1 | 1 | ||
| RGV005 | AXP000139 | CD19-CAR novel oncolytic vaccinia virus | vaccinia virus | conditionally replicating | Phase 1 | 1 | |
| TBio-6517 | AXP000104 | RIVAL-01 | vaccinia virus · Copenhagen | conditionally replicating | Phase 1 | 1 | |
| TG6002 | AXP000094 | T601, TG6002/5-FC | vaccinia virus · Copenhagen | conditionally replicating | Phase 1/2 | 4 | |
| TG6050 | AXP000096 | vaccinia virus · Copenhagen | conditionally replicating | Phase 1 | 1 | ||
| VET3-TGI | AXP000106 | vaccinia virus | conditionally replicating | Phase 1 | 1 | ||
| VV-GMCSF-Lact | AXP000111 | Double Recombinant Vaccinia Virus VV-GMCSF-Lact | vaccinia virus · LIVP | conditionally replicating | Phase 1 | 1 | |
| vvDD-hIL2-RG-1 | AXP000098 | vvDD-hIL2-2-RG-1 | vaccinia virus · Western Reserve | conditionally replicating | Phase 1 | 1 |
In vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| MQ710 | AXP000192 | MVAdeltaE5R-Flt3L-OX40L | vaccinia virus · MVA (E5R-deleted) | non replicating | Phase 1 | 1 |
Vaccine vector
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| ALVAC(2)-NY-ESO-1(M)/TRICOM | AXP000189 | vCP2292 | canarypox virus · ALVAC(2) | non replicating | Phase 1/2 | 3 | |
| ALVAC-CEA-B7.1 | AXP000188 | canarypox virus · ALVAC | non replicating | Phase 2 | 1 | ||
| ALVAC-HIV (vCP1521) | AXP000202 | vCP1521 | canarypox virus · ALVAC (vCP1521) | non replicating | Phase 3 | 4 | |
| ALVAC-HIV (vCP2438) | AXP000203 | vCP2438 | canarypox virus · ALVAC (vCP2438) | non replicating | Phase 2/3 | 4 | |
| CV301 | AXP000180 | CV301-V/F, CVAC-301, FPV-CV301 | vaccinia virus · MVA-BN prime; fowlpox (FPV-CV301) boost | non replicating | Phase 2 | 7 | |
| mesmulogene ancovacivec | AXP000181 | TG4010, MVA-MUC1-IL2 | vaccinia virus · MVA | non replicating | Phase 2/3 | 5 | |
| MVA E2 | AXP000191 | MVA E2 therapeutic vaccine | vaccinia virus · MVA | non replicating | 0 | ||
| MVA-5T4 | AXP000184 | TroVax, OXB-301 | vaccinia virus · MVA | non replicating | Phase 3 | 11 | |
| MVA-BN-Brachyury-TRICOM | AXP000185 | BN-Brachyury, FPV-Brachyury-TRICOM, MVA-BN-Brachyury | vaccinia virus · MVA-BN prime; fowlpox (FPV-Brachyury) boost | non replicating | Phase 2 | 6 | |
| MVA-BN-Filo | AXP000201 | Mvabea | vaccinia virus · MVA-BN | non replicating | Phase 3 | withdrawn | 22 |
| MVA-BN-HER2 | AXP000186 | BN-HER2 | vaccinia virus · MVA-BN | non replicating | Phase 1 | 2 | |
| MVA-BN-RSV | AXP000204 | vaccinia virus · MVA-BN | non replicating | Phase 3 | 5 | ||
| p53MVA | AXP000187 | MVA-p53 | vaccinia virus · MVA | non replicating | Phase 2 | 4 | |
| PANVAC | AXP000179 | falimarev, inalimarev, PANVAC-F | vaccinia virus · PANVAC-V (vaccinia) prime; PANVAC-F (fowlpox) boost | replicating | Phase 3 | 6 | |
| rilimogene galvacirepvec/rilimogene glafolivec | AXP000178 | rilimogene galvacirepvec, rilimogene glafolivec, PROSTVAC | vaccinia virus · PROSTVAC-V (vaccinia) prime; PROSTVAC-F (fowlpox) boost | replicating | Phase 3 | 21 | |
| TA-HPV | AXP000190 | Human Papillomavirus Tumor Antigen Vaccine | vaccinia virus | replicating | Phase 2 | 4 | |
| TG4050 | AXP000183 | vaccinia virus · MVA | non replicating | Phase 1/2 | 2 | ||
| tipapkinogene sovacivec | AXP000182 | TG4001, MVA-HPV-IL2, MVA-HPV16E6/E7-IL2 | vaccinia virus · MVA | non replicating | Phase 2 | 2 |
Retroviridae (14)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| vocimagene amiretrorepvec | AXP000126 | Toca 511 | murine leukemia virus · amphotropic MLV-based replicating vector | replicating | Phase 2/3 | 10 |
In vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| Rexin-G | AXP000210 | Mx-dnG1, DeltaRex-G, Retrovector Encoding Mutant Anti-Cyclin G1 | murine leukemia virus · MoMLV-based pathotropic vector | non replicating | Phase 2 | yes (other) | 6 |
Ex vivo gene transfer
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| anitocabtagene autoleucel | AXP000022 | anito-cel, CART-ddBCMA | lentivirus | non replicating | Phase 3 | 8 | |
| axicabtagene ciloleucel | AXP000014 | Yescarta, KTE-C19, axi-cel | retrovirus | non replicating | Phase 4 | yes (FDA, EMA, PMDA) | 58 |
| brexucabtagene autoleucel | AXP000015 | Tecartus, KTE-X19, brexu-cel | retrovirus | non replicating | Phase 2 | yes (FDA, EMA) | 21 |
| ciltacabtagene autoleucel | AXP000018 | Carvykti, JNJ-4528, JNJ-68284528 | lentivirus | non replicating | Phase 4 | yes (FDA, EMA, PMDA) | 22 |
| equecabtagene autoleucel | AXP000021 | Fucaso, CT103A, IBI326 | lentivirus | non replicating | Phase 3 | yes (NMPA) | 12 |
| idecabtagene vicleucel | AXP000017 | Abecma, bb2121, ide-cel | lentivirus | non replicating | Phase 3 | yes (FDA, EMA, PMDA) | 19 |
| lisocabtagene maraleucel | AXP000016 | Breyanzi, JCAR017, liso-cel | lentivirus | non replicating | Phase 3 | yes (FDA, PMDA, EMA) | 36 |
| obecabtagene autoleucel | AXP000019 | Aucatzyl, AUTO1, obe-cel | lentivirus | non replicating | Phase 2 | yes (FDA, EMA) | 8 |
| relmacabtagene autoleucel | AXP000020 | Carteyva, JWCAR029, relma-cel | lentivirus | non replicating | Phase 4 | yes (NMPA) | 20 |
| Strimvelis | AXP000211 | GSK2696273 | murine leukemia virus · MoMLV-derived gamma-retroviral vector (GSK3336223) | non replicating | Phase 4 | yes (EMA) | 5 |
| tisagenlecleucel | AXP000013 | Kymriah, CTL019, tisa-cel | lentivirus | non replicating | Phase 3 | yes (FDA, EMA, PMDA) | 55 |
| Zalmoxis | AXP000212 | murine leukemia virus · SFCMM-3 Mut2 #48 | non replicating | yes (EMA) | 0 |
Rhabdoviridae (8)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| BI 1831169 | AXP000120 | vesicular stomatitis Indiana virus · VSV-GP chimera | replicating | Phase 1 | 2 | ||
| MG1-MAGEA3 | AXP000121 | MG1MA3, MG1 Maraba/MAGE-A3 | Maraba virus · MG1 (G Q242R, M L123W) | replicating | Phase 1/2 | 3 | |
| OVV-01 | AXP000132 | oncolytic virus (OVV-01) injection | vesicular stomatitis Indiana virus · Indiana, recombinant | replicating | Phase 2 | 5 | |
| Revottack | AXP000134 | vesicular stomatitis Indiana virus | replicating | Phase 1 | 1 | ||
| VSV-02 | AXP000133 | VSV-02 Injection | vesicular stomatitis Indiana virus · attenuated | replicating | Phase 1 | 1 | |
| VSV-hIFNbeta | AXP000136 | Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta, VSV-hIFN-b | vesicular stomatitis Indiana virus · Indiana, recombinant | replicating | Phase 2 | 6 | |
| VSV-IFNbeta-NIS | AXP000119 | Voyager-V1, VSV-hIFNbeta-NIS, VSV-IFNb-NIS | vesicular stomatitis Indiana virus · Indiana, recombinant | replicating | Phase 2 | 7 |
Vaccine vector
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| rVSVΔG-ZEBOV-GP | AXP000205 | Ervebo, rVSV-ZEBOV | vesicular stomatitis Indiana virus · Indiana, rVSVΔG | replicating | Phase 4 | yes (EMA, FDA) | 14 |
Spinareoviridae (1)
Oncolytic
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| pelareorep | AXP000004 | Reolysin, PO-BB0209 | mammalian orthoreovirus · type 3 Dearing | replicating | Phase 3 | 35 |
Straboviridae (1)
Phage
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| T4 coliphage cocktail (Nestlé) | AXP000245 | T4 phage cocktail | Escherichia coli T4-like bacteriophage (cocktail) | replicating | 1 |
Togaviridae (4)
Oncolytic
Vaccine vector
| Program | ID | Also known as | Virus · strain | Replication | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|---|
| AVX701 | AXP000213 | CEA(6D) VRP | Venezuelan equine encephalitis virus · VEE replicon, packaged as virus-like replicon particles | non replicating | Phase 1/2 | 2 | |
| AVX901 | AXP000214 | HER2 ECDTM VRP, VRP-HER2 | Venezuelan equine encephalitis virus · VEE replicon, packaged as virus-like replicon particles | non replicating | Phase 2 | 2 |
Targeted small molecule (10)
| Program | ID | Also known as | Platform · targets | Highest phase | Approved | Trials |
|---|---|---|---|---|---|---|
| adagrasib | AXP000024 | Krazati, MRTX849 | small molecule · KRAS | Phase 3 | 39 | |
| daraxonrasib | AXP000027 | Rasonque, RMC-6236 | small molecule · KRAS; NRAS; HRAS | Phase 3 | 22 | |
| divarasib | AXP000025 | GDC-6036, RG6330 | small molecule · KRAS | Phase 3 | 15 | |
| elironrasib | AXP000028 | RMC-6291 | small molecule · KRAS | Phase 1/2 | 4 | |
| fulzerasib | AXP000031 | Dupert, GFH925, IBI351 | small molecule · KRAS | Phase 3 | 14 | |
| glecirasib | AXP000030 | 艾瑞凯, JAB-21822 | small molecule · KRAS | Phase 3 | 17 | |
| MRTX1133 | AXP000026 | small molecule · KRAS | Phase 1 | 1 | ||
| olomorasib | AXP000032 | LY3537982 | small molecule · KRAS | Phase 3 | 18 | |
| sotorasib | AXP000023 | Lumakras, Lumykras, AMG 510 | small molecule · KRAS | Phase 4 | 71 | |
| zoldonrasib | AXP000029 | RM-036, RMC-9805 | small molecule · KRAS | Phase 3 | 8 |